F-1: Clearmind Medicine Registers 5.78M Shares for Resale

Clearmind Medicine Inc. filed an F-1 registration statement for the resale of up to 5,781,250 common shares by selling shareholders, stemming from warrant exercises and recent financing activities, while addressing Nasdaq listing compliance.

Summary

• The company filed an F-1 registration statement for the resale of up to 5,781,250 common shares by identified selling shareholders, which are issuable upon the exercise of January 2024 PIPE Warrants.
• Clearmind Medicine is a clinical pharmaceutical company engaged in Phase I/IIa clinical trials for novel psychedelic medicines targeting Alcohol Use Disorder (AUD), binge drinking, eating disorders, obesity, and metabolic disorders.
• The company received a Nasdaq notification on November 3, 2025, for non-compliance with the Minimum Stockholders' Equity Rule, reporting $1,065,668 as of July 31, 2025, against a required $2,500,000.
• Recent financing activities include the conversion of $2.5 million in convertible promissory notes into 5,171,460 Common Shares and registered direct offerings in November 2025 raising approximately $0.788 million, $1.377 million, and $2.185 million.
• Warrant exercises as of November 14, 2025, generated approximately $183,000 in gross proceeds and resulted in the issuance of 2,090,987 common shares.
• The company expects these recent financings and warrant exercises to help regain compliance with Nasdaq's stockholders' equity requirement.
• The audit report for the year ended October 31, 2024, includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern due to recurring losses from operations and lack of sufficient resources.

Sentiment

Score: 3

Explanation: While the company is making progress in clinical trials and has recently raised capital, the significant Nasdaq non-compliance and the 'going concern' warning from auditors indicate substantial financial instability and high risk. The capital raises are reactive to these issues, not necessarily indicative of strong underlying performance.

Positives

• Progress in Phase I/IIa clinical trials for CMND-100 in patients with AUD, with multiple clinical sites initiated in Israel (Tel Aviv Sourasky Medical Center, Hadassah-University Medical Center) and the United States (Yale School of Medicine, Johns Hopkins University School of Medicine).
• Pre-clinical research for MEAI demonstrated anti-obesity effects, including significantly reduced diet-induced obesity and adiposity, positive effects on glycemic control, and reduced hepatic steatosis.
• Pre-clinical studies suggest MEAI may be effective in treating substance addiction, specifically cocaine, without interrupting the natural reward process.
• Successfully raised approximately $4.35 million through three registered direct offerings in November 2025.
• Converted $2.5 million in convertible promissory notes into 5,171,460 Common Shares, which is expected to improve the balance sheet and aid Nasdaq compliance.
• Received approximately $183,000 from the cash exercise of warrants as of November 14, 2025.

Negatives

• Received a Nasdaq notification on November 3, 2025, for non-compliance with the Minimum Stockholders' Equity Rule, reporting $1,065,668 as of July 31, 2025, against a required $2,500,000.
• The audit report for the year ended October 31, 2024, includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern due to recurring losses from operations and lack of sufficient resources.
• The company will not receive any proceeds from the sale of common shares by the selling shareholders in this specific registration, only from warrant exercises if not cashless.
• Investing in the company's securities involves a high degree of risk.
• The sale of 5,781,250 common shares by selling shareholders, along with potential future issuances, could result in substantial dilution to existing shareholders.
• The common shares traded at a low price of $0.16 on Nasdaq and EUR 0.1684 (approximately $0.19) on the Frankfurt Stock Exchange as of November 25, 2025.

Risks

• The sale of a substantial amount of common shares by selling shareholders in the public market, or the perception of such sales, could adversely affect the prevailing market price of the common shares and result in substantial dilution.
• Operations are located in Israel, and political, economic, and military conditions in the Middle East, including ongoing conflicts and potential for renewed hostilities, may adversely affect business operations, supply chains, and financial condition.
• Failure to regain and maintain compliance with Nasdaq's continued listing requirements could result in the delisting of common shares, substantially decreasing trading, adversely affecting market liquidity, and hindering the ability to obtain financing.
• The company is dependent on third parties for conducting clinical trials, manufacturing, and commercialization of its drug candidates.
• There is no assurance that the company will obtain and maintain regulatory approval for its future product candidates.
• The company faces competition from other companies offering products that address similar issues.
• Additional financing will be required to fund further clinical trials and operations, and there is no guarantee it will be available on acceptable terms.
• There is uncertainty regarding the ability of pre-clinical and future clinical trials to demonstrate the safety and efficacy of product candidates.
• Insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East, and government coverage may not be sufficient.
• There is uncertainty with respect to whether a Canadian court would take jurisdiction on a matter of liability predicated solely upon U.S. federal securities laws, or enforce a foreign judgment on such liabilities.

Future Outlook

The company aims to continue its Phase I/IIa clinical trials for CMND-100 in AUD and other indications, with plans for additional clinical trials subject to securing further financing. It intends to seek regulatory approval through the FDA's 505(b)(1) path for novel drugs. Management expects recent financing activities and warrant exercises to enable the company to demonstrate compliance with Nasdaq's minimum stockholders' equity requirement. The company believes its MEAI treatment has the potential to address significant unmet needs in mental health disorders, including AUD, binge drinking, obesity, and metabolic disorders, and could potentially reduce healthcare costs.

Management Comments

• "We believe that our solution for AUD can help solve one of the world's biggest health problems, which costs the United States alone roughly $250 billion each year."
• "Apart from potentially changing people's lives, we believe that our treatment could potentially reduce the amount currently being spent on the consequences of AUD in the United States, Europe, India, China and other countries around the world."
• "We believe that our drug candidate has the potential to change the lives of millions who struggle to drink in moderation."
• "We believe that MEAI holds the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to sensible behavior."
• "We expect that we will be able to demonstrate compliance with the Nasdaq stockholders equity requirement as a result of such financing and warrant exercises."

Industry Context

Clearmind Medicine operates in the emerging and rapidly evolving psychedelic medicine industry, focusing on novel treatments for mental health disorders and addictions, such as Alcohol Use Disorder (AUD), binge drinking, obesity, and metabolic disorders. This sector is characterized by significant unmet medical needs and a growing interest in alternative therapies, with companies like Clearmind seeking to leverage previously overlooked compounds. The company's focus on non-hallucinogenic neuroplastogens like MEAI positions it within a niche aiming for therapeutic benefits without the psychedelic experience, potentially broadening market acceptance. The high costs associated with AUD globally ($250 billion annually in the U.S. alone) highlight the substantial market opportunity for effective treatments.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry.
• The company is pursuing the FDA's 505(b)(1) regulatory path, typically used for novel drugs, which requires extensive research to prove safety and efficacy, aligning with standard pharmaceutical development for new chemical entities.
• Pre-clinical studies for MEAI in obesity and metabolic disorders, and addiction, show promising results, but these are early-stage findings and require further clinical validation to be compared to established treatments or competitors.
• The company's clinical trial initiation at prestigious institutions like Yale and Johns Hopkins suggests a commitment to rigorous scientific validation, which is a positive indicator within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Face potential for significant dilution from the resale of 5,781,250 common shares and future capital raises. There is a risk of delisting from Nasdaq, which could severely impact share price and liquidity. Investing in the company's securities involves a high degree of risk.
• Employees: Operations in Israel expose employees to geopolitical risks, though currently, no employees are serving in active military duty. Renewed conflict could impact their work environment.
• Customers/Patients: Potential for new treatments for AUD, binge drinking, obesity, and metabolic disorders if clinical trials are successful and regulatory approval is obtained, addressing significant unmet medical needs.
• Creditors: The 'going concern' warning from auditors indicates increased risk for creditors due to recurring losses and insufficient resources.

Next Steps

• Submit a plan to Nasdaq by December 18, 2025, to regain compliance with the Minimum Stockholders' Equity Rule.
• Continue Phase I/IIa clinical trials for CMND-100 in AUD and other indications.
• Conduct additional clinical trials for product candidates, subject to securing additional financing.
• Seek regulatory approval through the FDA's 505(b)(1) regulatory path.
• Management will retain broad discretion over the use of any proceeds from warrant exercises for general corporate purposes, including R&D, working capital, and potential acquisitions.

Key Dates

Recommendation

The company faces immediate and severe financial challenges, including non-compliance with Nasdaq's minimum stockholders' equity requirement and an auditor's 'going concern' warning due to recurring losses. While recent capital raises provide some temporary relief, they also contribute to significant shareholder dilution. The geopolitical risks associated with operations in Israel add another layer of uncertainty. The early-stage nature of its clinical pipeline means that any potential future success is highly speculative and far off, making the current financial instability and delisting risk paramount. A seasoned investor would likely view these factors as strong indicators to exit the position.

Keywords

Clearmind Medicine, CMND, F-1 Registration, SEC filing, psychedelic medicine, AUD treatment, obesity treatment, MEAI, clinical trials, Nasdaq compliance, stockholders equity, warrant resale, capital raise, going concern, biotechnology, pharmaceuticals, mental health, addiction treatment, neuroplastogens